A pathology second opinion for glioblastoma means sending your tumor tissue or digital images to a neuropathologist who did not work on your original diagnosis. The expert reviews the microscope appearance and molecular test results. The process is remote and can happen while you are getting treatment or deciding on a plan.
How to Get a Glioblastoma Pathology Second Opinion
- Request your full pathology report from the hospital, not just the one-page summary.
- Request your tumor tissue materials - typically unstained glass slides, a formalin-fixed paraffin-embedded (FFPE) tissue block, or a digital whole-slide image (WSI) file. Each has different shipping requirements.
- Gather your MRI scans - most reviewing centers want imaging with pathology because some diagnostic decisions need both pieces together.
- Contact a specialist neuropathology center and confirm what material formats they accept and whether they handle international cases.
- Ship or upload your materials following the center's instructions - glass slides travel by insured courier in a slide mailer; digital files go through a secure upload portal.
- Receive the second-opinion report, typically within 5 to 14 business days depending on the center.
- Discuss the findings with your oncologist and, if the diagnosis has changed, ask how it affects your treatment options.
Why a Pathology Review Is Different from a Treatment Second Opinion
Many patients seek a second opinion on treatment - whether to add tumor treating fields, whether a clinical trial fits, or how to handle a recurrence. That is a different question from a pathology second opinion, which asks something more fundamental: is the diagnosis itself correct?
Both types of review matter and go together. For anyone who doubts their original diagnosis, or whose tissue was processed at a center with limited brain tumor experience, the pathology review should come first. A treatment plan built on an incomplete or incorrect molecular diagnosis may not target the right vulnerabilities.
If you want to understand what a neuro-oncology team reviews in a full second opinion beyond pathology alone, see our guide on remote second opinion for glioblastoma: how to prepare your materials and what to expect from virtual consultation.
Why Your Pathology Report May Not Tell the Full Story
Brain tumor classification changed with the 2021 World Health Organization update to CNS tumor grading. What was previously diagnosed by microscope appearance alone now requires an integrated molecular profile. According to an analysis of the 2021 WHO CNS tumor classification published in Neuro-Oncology Practice, a tumor can now be classified as IDH-wildtype glioblastoma based on molecular markers such as TERT promoter mutation or EGFR amplification - even when it appears lower-grade under the microscope.
The reverse is equally important. A tumor that looks like glioblastoma under the microscope may carry an IDH mutation that reclassifies it as IDH-mutant astrocytoma - a different disease with different treatment considerations. Getting that distinction right affects every subsequent decision, from which chemotherapy works to which clinical trials you qualify for.
MGMT promoter methylation is a separate but equally critical test. It predicts whether temozolomide chemotherapy will work. Research shows that methylated status is linked to better outcomes in IDH-wildtype glioblastoma. If your original pathology report does not mention MGMT testing, that is a gap a second-opinion neuropathologist can identify - and may be able to address using the existing tissue block, without needing a repeat biopsy.
The National Brain Tumor Society notes that glioblastoma is rare and should ideally be reviewed by a neuropathologist familiar with these tumors at a large academic institution with a neuro-oncology team. Not all centers meet this standard, especially smaller hospitals without neuro-oncology programs.
To understand what each term in your original pathology report means, see what your glioblastoma pathology report really means.
What a Remote International Pathology Review Actually Covers
Not every center offers the same scope of review. Before sending materials, ask the reviewing center exactly what their second opinion includes.
Histological re-examination
A neuropathologist examines the stained slides to check tumor type, grade, and any missed or differently interpreted features.
Molecular marker completeness check
The reviewer checks that all required markers were tested. For glioblastoma, this means at minimum: IDH1/2 mutation status, TERT promoter mutation, EGFR amplification, chromosome 7 gain / chromosome 10 loss, and MGMT promoter methylation. Missing markers need to be addressed before you finalize treatment.
Supplementary molecular testing
If some tests are missing and the tissue block is available, the center can run them. You won't need another biopsy, which is a big advantage since you already had surgery.
WHO 2021-aligned integrated diagnosis
The report should give the final diagnosis using current WHO standards. This gives everyone working with you the same, current classification instead of an old label.
Written formal report
You should get a signed report you can share with your team, submit to clinical trials, or show a new center. Some centers offer a call to discuss the findings. Ask about this when you contact them.
What to Send and How to Send It
Most neuropathology centers accept one or more of the following material types. Check what the center wants before asking your hospital, since requirements vary.
Tissue materials
- Unstained glass slides - these are most common. Centers ask for 5 to 10 slides, shipped in a protective box by courier.
- FFPE tissue block - a paraffin wax block with embedded tumor tissue. Sending the block lets the lab cut new samples and run more tests. Some hospitals keep the block and just lend it for the review.
- Digital whole-slide images (WSI) - scans you upload instead of shipping slides. Studies show digital review works as well as traditional review at expert centers. Not all hospitals have scanning equipment, especially smaller ones.
Supporting documents
- Full pathology report with all test results, not just the summary
- Surgery report from the biopsy or resection
- MRI scans with contrast on a USB drive (not printed)
- Any prior molecular or genetic test results, including next-generation sequencing reports if available
The National Cancer Institute notes that you have the right to request copies of your pathology reports and ask that slides go to another center. Ask your hospital's pathology department.
How Long Does an International Pathology Review Take?
Timeline depends on how fast you get materials, how you send them, and how fast the center reviews.
Getting slides takes 3 to 10 days, or longer if no one pushes the hospital. Shipping takes 3 to 7 days. Digital upload is fast, but many hospitals can't scan slides.
Review usually takes 5 to 14 days. Extra molecular tests take 2 to 4 more weeks.
Expect 3 to 6 weeks total if you send physical slides internationally. Digital pathology can be done in under 2 weeks if both hospitals can do it. If you're in treatment, ask your doctor about starting treatment while the review happens.
What Happens If the Second Opinion Finds Something Different?
A diagnosis change can be hard, but it's not always bad. It might open new treatment options, fix a wrong plan, or get you into a clinical trial you'd missed. Better to know before you start.
If the two reports conflict, work through the following steps:
- Bring both reports to your oncologist and have them explain the difference. A meeting is better than a call for complex cases.
- Request a tumor board review if the difference changes treatment. A tumor board at a specialist center can resolve disagreements faster than sending messages between hospitals.
- Reassess your treatment plan with the revised diagnosis in hand. It might change your chemo, clinical trial options, or outlook.
Changing diagnoses are frustrating. If you're unsure what your treatment options look like after a revised or complex pathology result, you can arrange a remote second opinion through Art of Healing Cancer, whose team works with patients worldwide on complex cases and can help explain conflicting pathology in your treatment plan.
For more on when and why a second opinion changes a treatment path, see when to seek a glioblastoma second opinion.
How to Evaluate a Center for International Pathology Review
Not all hospitals can handle remote international reviews. When choosing a center, look for these:
- A neuropathology division or a pathologist trained in brain tumors, not general pathology
- The ability to run full molecular tests on tissue blocks, not just look at slides
- Clear instructions for sending materials and uploading files
- A signed report in English (or another language) with the full WHO diagnosis
The National Brain Tumor Society recommends asking for review at a large cancer center with a neuro-oncology team and neuropathologist. This applies whether the review is in person or remote.
When to Talk to Your Doctor
Ask your doctor about a second opinion if: your report is missing IDH, TERT, or MGMT results; your diagnosis came from a hospital without a neuro-oncology team; you were told the diagnosis is uncertain; or you're looking at clinical trials with specific requirements. Ask if the review will delay your treatment, and what you'll do if the result is different. Your doctor can often speed up getting the slides.
If you are ready to take a next step, you can submit your reports and MRI through the Glioblastoma Center to request a review.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.